Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis
Robert Wolk, Ehrin J Armstrong, Peter R Hansen, Bruce Thiers, Shuping Lan, Anna M Tallman, Mandeep Kaur, Svitlana Tatulych, Robert Wolk, Ehrin J Armstrong, Peter R Hansen, Bruce Thiers, Shuping Lan, Anna M Tallman, Mandeep Kaur, Svitlana Tatulych
Abstract
Background: Psoriasis is a systemic inflammatory disease associated with increased cardiovascular (CV) risk and altered lipid metabolism. Tofacitinib is an oral Janus kinase inhibitor.
Objective: The aim of the study was to investigate the effects of tofacitinib on traditional and nontraditional lipid parameters and CV risk markers in patients with psoriasis from a phase III study, OPT Pivotal 1.
Methods: Patients with psoriasis were randomized to tofacitinib 5 or 10 mg twice daily (BID) or placebo BID. Serum samples were collected at baseline, week 4, and week 16. Analyses included serum cholesterol levels, triglycerides, lipoproteins, lipid particles, lipid-related parameters/CV risk markers, and high-density lipoprotein (HDL) function analyses.
Results: At week 16, small concurrent increases in mean low-density lipoprotein cholesterol (LDL-C) and HDL cholesterol (HDL-C) levels were observed with tofacitinib; total cholesterol/HDL-C ratio did not change. There was no significant change in the number of small dense LDL particles, which are considered to be more atherogenic than large particles, and oxidized LDL did not increase. Paraoxonase 1 activity, linked to HDL antioxidant capacity, increased, and HDL-associated serum amyloid A, which reduces the anti-atherogenic potential of HDL, decreased. HDL capacity to promote cholesterol efflux from macrophages did not change. Lecithin-cholesterol acyltransferase activity, which is associated with reverse cholesterol transport, increased. Markers of systemic inflammation, serum amyloid A and C-reactive protein, decreased with tofacitinib.
Conclusion: While small increases in lipid levels are observed with tofacitinib treatment in patients with psoriasis, effects on selected lipid-related parameters and other circulating CV risk biomarkers are not suggestive of an increased CV risk [NCT01276639].
Keywords: Cardiovascular risk; HDL function; Lipid levels; Lipid metabolism; Lipoproteins; Psoriasis; Tofacitinib.
Copyright © 2017 National Lipid Association. Published by Elsevier Inc. All rights reserved.
Source: PubMed